Hoth Therapeutics secured regulatory approval in Spain for its Phase 2a CLEER Trial of HT-001, a topical treatment aimed at reducing skin toxicities caused by EGFR inhibitor cancer therapies. Interim results show over 65% of patients experienced significant relief from rash, pain, and itching, with no need to reduce or stop their cancer treatment. The trial's success supports Hoth's plan to expand the study across Europe, potentially improving quality of life and treatment adherence for cancer patients. This marks a key step in developing supportive care options in oncology.
T3 Defense's stock soared 201% following its subsidiary's expansion of defense technology into industrial materials, signaling strong growth potential. NextCure saw a 20.75% rise driven by a significant short squeeze, reflecting heavy short interest ...
Environics Analytics has named Cenker Ozhelvaci as Head of Sales for its core direct sales teams. Ozhelvaci brings extensive experience from sectors like financial services and technology, having previously led sales at Provenir and Amazon Canada. Hi...
AT&T reported better-than-expected earnings and announced a $10 billion share buyback program. Despite the positive results and buyback plan, the stock still trades at a relatively low valuation of 8 times earnings and offers a 4.6% dividend yield. T...
AstraZeneca reported a 21% increase in core earnings per share to $2.63 for Q2 2026, surpassing analyst expectations of $2.50. Total revenue rose 6% to $15.38 billion, driven by strong sales in oncology and rare disease drugs, offsetting pressure fro...
American Tower Corporation's analyst price targets have dropped from $218.24 to $188 over the past year, reflecting cautious market sentiment. However, the company reported a robust 6.8% revenue growth in Q1 2026, driven by its international towers a...
